Highly specialised reconstruction · UK
Face transplantation — an honest UK patient guide.
Around fifty face transplants have been performed anywhere in the world since 2005. No UK hospital currently performs one. This page is an honest read of what the option involves, who it is for, and how referral overseas actually works.
Why patients come to us
- 01
An honest read of a very rare option
Fewer than fifty face transplants have been performed anywhere in the world. We tell you what that means for your case before anything else.
- 02
UK reality, not marketing
No hospital in the UK currently performs face transplantation. If your case is exceptional, referral runs through NHS England to Cleveland, Boston, NYU, Uppsala or Amiens.
- 03
Independent, and free
We are paid by no clinic and no overseas centre, so the guidance is impartial and costs you nothing.
Indicative pricing
What a face transplant pathway actually costs.
Broad ranges only. If NHS England approves your case for exceptional funding, the operation and follow-up are covered. Self-pay overseas is a different order of magnitude.
In short
NHS England funding if approved, otherwise £800k–£1.5m+ at an overseas centre, plus £15k–£40k a year for lifelong immunosuppression.
| Pathway | Indicative range | Typical duration | Follow-up |
|---|---|---|---|
| NHS England Highly Specialised Services referral (exceptional funding) | Funded if approved | Months of review | Case-by-case |
| Overseas centre self-pay (Cleveland / Boston / NYU) | £800k–£1.5m+ | Multi-year | Case-by-case |
| Lifetime immunosuppression and follow-up | £15k–£40k / year | Lifelong | Ongoing |
| Multidisciplinary work-up (psychology, immunology, imaging) | £20k–£60k | 6–24 months | Staged |
| Conventional reconstructive alternative (staged flap surgery) | £40k–£200k | 1–3 years | Staged |
| Consultation only (Pulse Atlas navigation) | Free | 45–60 min | Same visit |
The numbers vary widely by centre, by scope of the transplant (partial, full, face-plus-hands), and by complications. Our job is to be honest about them before anyone gets on a plane.
The problem
The right MDT, the right honesty, the right pathway.
Face transplantation is discussed far more often online than it is performed. Most patients who ask about it are better served by staged reconstruction, prosthetics, or psychological support — and we say so, plainly, before anyone raises expectations.
-
Not sure it is even possible?
Fewer than fifty have been performed globally. We say honestly whether your case is anywhere close to being a candidate.
-
Worried about the trade?
Lifelong immunosuppression is the real cost. The transplant team, and we, will not sugar-coat it.
-
Want a route into a UK MDT?
A named UK plastic surgery MDT, an ethics conversation, and — where warranted — the NHS England exceptional funding pathway.
The journey
From enquiry to lifelong follow-up — what happens, in order.
Years, not weeks. Every stage exists for a reason — and every stage can conclude that VCA is not the right answer.
Phase 1 · Before the operation
Concierge and MDT work-up
Phase 2 · The operation and hospital stay
Weeks to months in hospital
Phase 3 · After
Lifelong follow-up
- 01
Before
You tell us what happened
A confidential form. Nature of the injury or condition, previous reconstructions, current function — airway, feeding, vision, speech.
- 02
Before
We come back with an honest read
Within a few working days: whether face transplantation is even on the table, what conventional reconstruction can still offer, and which UK MDT to speak to first.
- 03
Before
MDT work-up over months to years
Plastic surgery, transplant medicine, immunology, psychology, psychiatry, dentistry, ENT, ophthalmology, social work and ethics. Nothing is rushed.
- 04
Operation & hospital
The transplant itself
Twenty to forty hours in theatre, dual donor and recipient teams, microvascular anastomosis, nerve coaptation, bony fixation. Then two to four weeks in ICU.
- 05
Operation & hospital
The first hospital months
A stepped-down surgical ward stay of several months. Early rejection episodes are common and treated aggressively with pulse steroids.
- 06
After
Function returns over a year or two
Sensory return over six to eighteen months, motor recovery over one to two years, functional speech, eating and breathing by year two.
- 07
After
Lifelong follow-up
Lifetime immunosuppression, surveillance for rejection, infection and malignancy, and open access to the transplant team.
Typical end-to-end: 1–3 years from enquiry to operation. Follow-up: lifelong.
When it helps
When face transplantation is genuinely on the table.
The clinical situations that have led to the world’s fifty or so face transplants — plus the one absolute red flag.
-
Severe ballistic facial injury
Shotgun or firearm injuries destroying mid-face, mandible, nose, lips and eyelids beyond conventional flap reconstruction.
-
Extensive full-thickness facial burns
Fourth-degree burns with loss of eyelids, nose, lips and cheek soft tissue, where staged reconstruction cannot restore function.
-
Animal maul injury
Bear, dog or primate attack with loss of central-face structures — the indication in several of the earliest recipients.
-
Severe neurofibromatosis of the face
Massive plexiform neurofibromas distorting the face, airway and vision that cannot be safely debulked.
-
Failed conventional reconstruction
Multiple flap procedures that have not restored eating, speech, blinking or a socially acceptable appearance.
-
Loss of eyelids and nose together
Combined loss of eyelids and nose is very difficult to reconstruct conventionally — a scenario where VCA is considered.
-
Congenital vascular malformation
Rare severe congenital malformations causing airway and feeding compromise, in adulthood, after conventional options are exhausted.
-
Red flag: active malignancy or infection
Untreated cancer, active infection or inability to tolerate lifelong immunosuppression are absolute reasons this cannot proceed.
Pathway options
Transplantation is not the only route.
What each realistic pathway actually involves — and which fits which situation.
-
Partial face transplant
Central lower or mid-face — lips, chin, cheeks, sometimes nose. The Amiens 2005 and several French and Spanish cases were partial.
-
Full face transplant
Forehead to chin including eyelids, nose, lips, cheeks and often underlying bone. Boston 2011 (Dallas Wiens) was the first full US case.
-
Face plus scalp
Extended VCA including scalp — performed at NYU Langone and Houston for extensive burns.
-
Face plus bilateral hands
Combined face and double-hand transplant. NYU Langone performed the first successful combined face-and-hands case (Isabel Boneta, 2023).
-
Conventional staged flap reconstruction
Multiple free-flap and local-flap procedures over years. The default option in the UK and the honest starting point for most patients.
-
Prosthetic facial rehabilitation
Silicone facial prosthetics, osseo-integrated implants and 3D-printed devices — much lower risk, often used alongside surgery.
-
Psychological support only
For some patients, an intensive psychological and social pathway is the right first step, not more surgery.
-
Consultation only
An honest discussion of whether transplantation is realistic at all, and which UK MDT to approach first — no obligation.
Our vetted network
A small network of UK MDTs and overseas centres, we chose them.
Named UK plastic and reconstructive MDTs first. Where an overseas referral is warranted, established relationships with Cleveland Clinic, Brigham & Women’s, NYU Langone, Uppsala and Amiens.
Selection criteria
How we choose every MDT and centre in our network.
-
UK MDTs at major plastic and reconstructive centres, not single surgeons in isolation
-
Clear pathway into NHS England Highly Specialised Services for exceptional funding review
-
Established relationships with the overseas centres performing face transplantation
-
Psychology, psychiatry and ethics involvement from the first conversation, not as a formality
Safety and outcomes
What to expect afterwards — honestly.
Face transplantation is life-changing where it works — and it comes with rejection, infection and malignancy risks, and lifelong medication. The trade must be understood before the work-up begins.
-
The UK does not yet perform face transplants
No UK hospital is currently commissioned to perform face transplantation. RCS and BAPRAS have both discussed a national programme, but none exists as of 2026.
-
Acute rejection is expected, not exceptional
Roughly eighty-five per cent of recipients experience at least one acute rejection episode in the first year. Skin is the most immunogenic organ transplanted.
-
Lifelong immunosuppression is the trade
Triple therapy — tacrolimus, mycophenolate and prednisolone — for life. This is the single biggest driver of long-term risk.
-
Opportunistic infection is a real risk
CMV, EBV, PJP, HHV-6 and aspergillus infections are all recognised. Antimicrobial prophylaxis is used and monitored for years.
-
PTLD and skin cancer risk are elevated
Post-transplant lymphoproliferative disorder — driven by EBV — and squamous cell skin cancer are both more common. Surveillance is lifelong.
-
Identity stays yours
The bony skeleton is yours, and the transplanted face does not resemble the donor. Recipients report an appearance that is neither previous self nor donor.
-
Donor family considerations are significant
A face is uniquely identifiable, and donor family engagement is one of the most sensitive parts of the pathway.
-
Graft loss and death are possible
Approximately twenty per cent graft loss and ten per cent mortality at five years, largely from infection, malignancy and cardiovascular disease.
-
Red flags
Active malignancy, uncontrolled infection, poor psychological support, or inability to tolerate immunosuppression are all reasons this cannot go ahead.
Reading your MDT letter
Your MDT letter in four parts. Read the last one first.
Whichever MDT reviews your case, the letter you receive keeps to a similar shape.
A quiet reminder
Transplant language is precise and can read coldly — we translate it for you.
If you would like us to talk you through the letter before your next appointment, just ask.
- 01 Header
Indication and eligibility
Why VCA is being considered — burn, ballistic, neurofibromatosis, maul — and whether conventional options are genuinely exhausted.
- 02 Work-up
MDT, immunology and psychology summary
The outcome of surgical, transplant, immunological and psychological review, and the ethics committee’s position.
- 03 Findings
Sensitisation, imaging and donor matching
Panel-reactive antibody testing, 3D facial imaging, skin tone and blood group matching, and any barriers identified.
- 04 Impression
Recommendation and next step
Read this first: whether VCA is realistic, and — if so — which overseas programme is the most sensible next step, or which alternative pathway to pursue.
Recognised by major UK insurers
Private insurance does not, in practice, fund face transplantation. Funded routes run through NHS England Highly Specialised Services. We confirm what is and is not possible before anyone commits.
Frequently asked
Everything we get asked about face transplantation.
Quick answers on eligibility, cost, risk, immunosuppression and whether it is done in the UK at all.
-
Can I have a face transplant on the NHS in the UK?
Not routinely. No UK hospital currently performs face transplantation. In exceptional cases, patients are referred through NHS England Highly Specialised Services for funding to a centre abroad — typically Cleveland Clinic, Brigham & Women’s in Boston, NYU Langone, Uppsala in Sweden, or Amiens in France.
-
How many face transplants have been done in the world?
Around fifty since the first case in Amiens in 2005 (Isabelle Dinoire). Milestone cases include Connie Culp (Cleveland, 2008 — first US), Dallas Wiens (Boston, 2011 — first full US), Katie Stubblefield (Cleveland, 2018 — youngest recipient) and Isabel Boneta (NYU, 2023 — first Black US recipient and first successful combined face-and-hands case).
-
Who is a candidate?
Adults with catastrophic mid-face or full-face disfigurement — from burns, ballistic injury, animal maul, or severe neurofibromatosis — that affects airway, feeding, vision or speech and is beyond conventional reconstruction. Candidates must be psychologically robust, able to tolerate lifelong immunosuppression, and have strong family and social support. Active infection or malignancy rules it out.
-
What does the work-up involve?
Months to years of multidisciplinary review — plastic surgery, transplant medicine, immunology, psychology, psychiatry, dentistry, ENT, ophthalmology, social work and an ethics committee. Extensive 3D facial imaging, panel-reactive antibody testing for sensitisation, and detailed donor matching on skin tone, gender, age and blood group.
-
How long is the operation?
Between twenty and forty hours. A donor recovery team and a recipient team work in parallel. It involves microvascular joining of arteries and veins, coaptation of motor and sensory nerves, bony fixation, and staged closure. Intensive care follows for two to four weeks and hospital stay runs into months.
-
What immunosuppression is needed?
Induction with basiliximab or alemtuzumab, then lifelong maintenance with tacrolimus, mycophenolate and prednisolone. Acute rejection episodes — which occur in roughly eighty-five per cent of recipients within the first year — are treated with pulse steroids or thymoglobulin. Chronic rejection remains a long-term concern.
-
Will I look like the donor?
No. Your bony skeleton stays yours, and it is bone that drives facial identity. Recipients look neither like their previous self nor like the donor — the aesthetic outcome is generally reported at around seventy to eighty per cent of a natural face, with functional speech, eating and breathing usually restored by year two.
-
What are the biggest long-term risks?
Opportunistic infection (CMV, EBV, PJP, aspergillus, HHV-6), post-transplant lymphoproliferative disorder driven by EBV, elevated skin cancer risk (especially squamous cell carcinoma), diabetes and hypertension from steroids, and tacrolimus nephrotoxicity. Graft loss runs at around twenty per cent and mortality at around ten per cent at five years.
-
What does it cost?
If NHS England approves exceptional funding, the operation and follow-up are funded. Self-pay overseas is in the region of £800,000 to £1.5 million or more before ongoing immunosuppression, which itself costs £15,000 to £40,000 a year for life. Pulse Atlas navigation and the initial consultation are free.
Related tests and procedures
Looking for something else?
-
Reconstructive plastic surgery
Staged flap and free-tissue reconstruction after trauma or cancer.
Learn more -
Burns aftercare
Long-term burn scar management and reconstruction.
Learn more -
Prosthetic rehabilitation
Silicone and osseo-integrated facial prosthetics.
Learn more -
All tests and procedures
Every test and procedure we help patients navigate.
Learn more